62 62. Armenian SH, Sun CL, Kawashima T, et al. Long‐term health‐related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011; 118(5):1413–1420.
63 63. Sudour H, Mainard L, Baumann C, et al. Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transplant. 2009; 43(2):127–132.
64 64. Pillon M, Carucci NS, Mainardi C, et al. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplant. 2015; 50(3):414–419.
65 65. Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long‐term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007; 39:223–229.
66 66. Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart‐lung, and hematopoietic stem cell transplant. Pediatr Nephrol. 2008; 23(6):879–888.
67 67. Hingorani SR, Seidel K, Lindner A, et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008; 14(12):1365–1372.
68 68. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT‐associated thrombotic microangiopathy as multi‐system endothelial injury. Blood Reviews. 2015; 29(3):191–204.
69 69. Hingorani S. Kidney and bladder complications of hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. 5th edn. Chichester, UK: John Wiley & Sons, Ltd; 2016 pp. 1131–1141.
70 70. Vincent F, Costa MA, Rondeau E. Chronic renal failure: a nonmalignant late effect of allogeneic stem cell transplantation (Letter to the Editor). Blood. 2003; 102(7):2695–2696.
71 71. Barnett AH, Bain SC, Bouter P, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med. 2004; 351(19):1952–1961.
72 72. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review (Review). BMJ. 2004; 329(7470):828.
73 73. Petryk A, Bergemann TL, Polga KM, et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006; 91(3):899–905.
74 74. Kaste SC, Shidler TJ, Tong X, et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 33(4):435–441.
75 75. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87(7):3136–3141.
76 76. Bar M, Ott SM, Lewiecki EM, et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020; 9:S1083–8791. doi: 10.1016/j.bbmt.2020.07.001. Online ahead of print. PMID: 32653624
77 77. Carpenter PA, Hoffmeister P, Chesnut CH III, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2007; 13:683–690.
78 78. Kuhlen M, Bader P, Sauer M, et al. Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high‐risk or relapsed ALL ‐ results of the ALL‐SCT 2003 trial. Br J Haematol. 2018; 183(1):104–109.
79 79. Li X, Brazauskas R, Wang Z, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014; 20(4):587–592.
80 80. Nishimura T, Matsumoto T, Nishino M, Tomita K. Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res. 1997( 334):37–42.
81 81. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br. 1995; 77(1):34–41.
82 82. Mont MA, Cherian JJ, Sierra RJ, et al. Nontraumatic osteonecrosis of the femoral head: Where do we stand today? A ten‐year update. J Bone Joint Surg Am. 2015; 97(19):1604–1627.
83 83. Chughtai M, Piuzzi NS, Khlopas A, et al. An evidence‐based guide to the treatment of osteonecrosis of the femoral head. Bone Joint J. 2017; 99–b(10):1267–1279.
84 84. Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019; 4(3):85–97.
85 85. Osmani F, Thakkar S, Vigdorchik J. The utility of conservative treatment modalities in the management of osteonecrosis. Bull Hosp Jt Dis. 2017; 75(3):186–192.
86 86. Li D, Yang Z, Wei Z, Kang P. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA‐compliant meta‐analysis of animal studies and clinical trials. Sci Rep. 2018; 8(1):1450.
87 87. Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid‐related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009; 40(2):235–239.
88 88. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005( 435):164–170.
89 89. Hua KC, Yang XG, Feng JT, et al. The efficacy and safety of core decompression for the treatment of femoral head necrosis: a systematic review and meta‐analysis. J Orthop Surg Res. 2019; 14(1):306.
90 90. Sugioka Y, Hotokebuchi T, Tsutsui H. Transtrochanteric anterior rotational osteotomy for idiopathic and steroid‐induced necrosis of the femoral head. Indications and long‐term results. Clin Orthop Relat Res. 1992( 277):111–120.
91 91. Seki T, Hasegawa Y, Masui T, et al. Quality of life following femoral osteotomy and total hip arthroplasty for nontraumatic osteonecrosis of the femoral head. J Orthop Sci. 2008; 13(2):116–121.
92 92. Powell GF, Brasel JA, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. I. Clinical evaluation of the syndrome. N Eng J Med. 1967; 276(23):1271–1278.
93 93. Powell GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Eng J Med. 1967; 276(23):1279–1283.
94 94. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid‐induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab. 1998; 83(8):2824–2829.
95 95. Tejani A, Butt KM, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation. 1989; 47(2):229–233.
96 96. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate‐day corticosteroid treatment after kidney transplantation. J Pediatr. 1992; 120(5):721–725.
97 97. Reimer LG, Morris HG, Ellis EF. Growth of asthmatic children during treatment with alternate‐day steriods. J Allergy Clin Immunol. 1975; 55(4):224–231.
98 98. Ketterl TG, Chow EJ, Leisenring WM, et al. Adipokines, inflammation, and adiposity in hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2018; 24(3):622–626.
99 99. Armenian SH, Chemaitilly W, Chen M, et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: The cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transplant. 2017; 23(2):201–210.
100 100. Kamel A, Norgren S, Elimam A, et al. Effects of growth hormone treatment in obese prepubertal boys. J Clin Endocrinol Metab. 2000; 85(4):1412–1419.
101 101. Sanders